In a report released yesterday, David Steinberg from Jefferies maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report), with a price target of $214.00. The company’s shares closed last Thursday at $167.07, close to its 52-week high of $178.64.
According to TipRanks.com, Steinberg is a 4-star analyst with an average return of 9.8% and a 51.3% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Supernus Pharmaceuticals, and Pacira Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $204.50 average price target, representing a 21.5% upside. In a report issued on April 20, Cowen & Co. also reiterated a Buy rating on the stock with a $200.00 price target.
Jazz Pharmaceuticals’ market cap is currently $9.72B and has a P/E ratio of 38.90. The company has a Price to Book ratio of 18.47.
Based on the recent corporate insider activity of 62 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.